Heterochromatin Protein 1: A Multiplayer in Cancer Progression
Abstract
:Simple Summary
Abstract
1. Introduction
2. Altered Expression and Roles of HP1s in Cancer
2.1. Breast Cancer
2.2. Ovarian Cancer
2.3. Cervical Cancer
2.4. Colorectal Cancer (CRC)
2.5. Lung Cancer
2.6. Liver Cancer
2.7. Pancreatic Cancer
2.8. Prostate Cancer
2.9. Osteosarcoma
2.10. Glioma
2.11. Leukemia
2.12. Other Cancers
3. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- James, T.C.; Elgin, S.C. Identification of a nonhistone chromosomal protein associated with heterochromatin in Drosophila melanogaster and its gene. Mol. Cell. Biol. 1986, 6, 3862–3872. [Google Scholar] [CrossRef] [PubMed]
- Singh, P.B.; Miller, J.R.; Pearce, J.; Kothary, R.; Burton, R.D.; Paro, R.; James, T.C.; Gaunt, S.J. A sequence motif found in a Drosophila heterochromatin protein is conserved in animals and plants. Nucleic Acids Res. 1991, 19, 789–794. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mathison, A.; Milech De Assuncao, T.; Dsouza, N.R.; Williams, M.; Zimmermann, M.T.; Urrutia, R.; Lomberk, G. Discovery, expression, cellular localization, and molecular properties of a novel, alternative spliced HP1gamma isoform, lacking the chromoshadow domain. PLoS ONE 2020, 15, e0217452. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cowieson, N.P.; Partridge, J.F.; Allshire, R.C.; McLaughlin, P.J. Dimerisation of a chromo shadow domain and distinctions from the chromodomain as revealed by structural analysis. Curr. Biol. 2000, 10, 517–525. [Google Scholar] [CrossRef]
- Ball, L.J.; Murzina, N.V.; Broadhurst, R.W.; Raine, A.R.; Archer, S.J.; Stott, F.J.; Murzin, A.G.; Singh, P.B.; Domaille, P.J.; Laue, E.D. Structure of the chromatin binding (chromo) domain from mouse modifier protein 1. EMBO J. 1997, 16, 2473–2481. [Google Scholar] [CrossRef] [Green Version]
- Maison, C.; Almouzni, G. HP1 and the dynamics of heterochromatin maintenance. Nat. Rev. Mol. Cell Biol. 2004, 5, 296–304. [Google Scholar] [CrossRef]
- Brasher, S.V.; Smith, B.O.; Fogh, R.H.; Nietlispach, D.; Thiru, A.; Nielsen, P.R.; Broadhurst, R.W.; Ball, L.J.; Murzina, N.V.; Laue, E.D. The structure of mouse HP1 suggests a unique mode of single peptide recognition by the shadow chromo domain dimer. EMBO J. 2000, 19, 1587–1597. [Google Scholar] [CrossRef] [Green Version]
- Bryan, L.C.; Weilandt, D.R.; Bachmann, A.L.; Kilic, S.; Lechner, C.C.; Odermatt, P.D.; Fantner, G.E.; Georgeon, S.; Hantschel, O.; Hatzimanikatis, V.; et al. Single-molecule kinetic analysis of HP1-chromatin binding reveals a dynamic network of histone modification and DNA interactions. Nucleic Acids Res. 2017, 45, 10504–10517. [Google Scholar] [CrossRef]
- Larson, A.G.; Elnatan, D.; Keenen, M.M.; Trnka, M.J.; Johnston, J.B.; Burlingame, A.L.; Agard, D.A.; Redding, S.; Narlikar, G.J. Liquid droplet formation by HP1alpha suggests a role for phase separation in heterochromatin. Nature 2017, 547, 236–240. [Google Scholar] [CrossRef] [Green Version]
- Nakayama, J.; Rice, J.C.; Strahl, B.D.; Allis, C.D.; Grewal, S.I. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 2001, 292, 110–113. [Google Scholar] [CrossRef] [Green Version]
- Fuks, F.; Hurd, P.J.; Deplus, R.; Kouzarides, T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res. 2003, 31, 2305–2312. [Google Scholar] [CrossRef] [PubMed]
- White, D.; Rafalska-Metcalf, I.U.; Ivanov, A.V.; Corsinotti, A.; Peng, H.; Lee, S.C.; Trono, D.; Janicki, S.M.; Rauscher, F.J., 3rd. The ATM substrate KAP1 controls DNA repair in heterochromatin: Regulation by HP1 proteins and serine 473/824 phosphorylation. Mol. Cancer Res. 2012, 10, 401–414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baldeyron, C.; Soria, G.; Roche, D.; Cook, A.J.; Almouzni, G. HP1alpha recruitment to DNA damage by p150CAF-1 promotes homologous recombination repair. J. Cell Biol. 2011, 193, 81–95. [Google Scholar] [CrossRef] [Green Version]
- Ayoub, N.; Jeyasekharan, A.D.; Bernal, J.A.; Venkitaraman, A.R. HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response. Nature 2008, 453, 682–686. [Google Scholar] [CrossRef]
- Fischle, W.; Tseng, B.S.; Dormann, H.L.; Ueberheide, B.M.; Garcia, B.A.; Shabanowitz, J.; Hunt, D.F.; Funabiki, H.; Allis, C.D. Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation. Nature 2005, 438, 1116–1122. [Google Scholar] [CrossRef]
- Canudas, S.; Houghtaling, B.R.; Bhanot, M.; Sasa, G.; Savage, S.A.; Bertuch, A.A.; Smith, S. A role for heterochromatin protein 1gamma at human telomeres. Genes Dev. 2011, 25, 1807–1819. [Google Scholar] [CrossRef] [Green Version]
- Dialynas, G.K.; Vitalini, M.W.; Wallrath, L.L. Linking Heterochromatin Protein 1 (HP1) to cancer progression. Mutat. Res. 2008, 647, 13–20. [Google Scholar] [CrossRef] [Green Version]
- Takanashi, M.; Oikawa, K.; Fujita, K.; Kudo, M.; Kinoshita, M.; Kuroda, M. Heterochromatin protein 1gamma epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers. Am. J. Pathol. 2009, 174, 309–316. [Google Scholar] [CrossRef] [Green Version]
- Norwood, L.E.; Moss, T.J.; Margaryan, N.V.; Cook, S.L.; Wright, L.; Seftor, E.A.; Hendrix, M.J.; Kirschmann, D.A.; Wallrath, L.L. A requirement for dimerization of HP1Hsalpha in suppression of breast cancer invasion. J. Biol. Chem. 2006, 281, 18668–18676. [Google Scholar] [CrossRef] [Green Version]
- Lee, Y.H.; Kuo, C.Y.; Stark, J.M.; Shih, H.M.; Ann, D.K. HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response. Nucleic Acids Res 2013, 41, 5784–5798. [Google Scholar] [CrossRef] [PubMed]
- Lieberthal, J.G.; Kaminsky, M.; Parkhurst, C.N.; Tanese, N. The role of YY1 in reduced HP1alpha gene expression in invasive human breast cancer cells. Breast Cancer Res. 2009, 11, R42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, Y.H.; Liu, X.; Qiu, F.; O’Connor, T.R.; Yen, Y.; Ann, D.K. HP1beta is a biomarker for breast cancer prognosis and PARP inhibitor therapy. PLoS ONE 2015, 10, e0121207. [Google Scholar] [CrossRef]
- De Koning, L.; Savignoni, A.; Boumendil, C.; Rehman, H.; Asselain, B.; Sastre-Garau, X.; Almouzni, G. Heterochromatin protein 1alpha: A hallmark of cell proliferation relevant to clinical oncology. EMBO Mol. Med. 2009, 1, 178–191. [Google Scholar] [CrossRef]
- Zhou, Q.; Atadja, P.; Davidson, N.E. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol. Ther. 2007, 6, 64–69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hsu, P.Y.; Hsu, H.K.; Hsiao, T.H.; Ye, Z.; Wang, E.; Profit, A.L.; Jatoi, I.; Chen, Y.; Kirma, N.B.; Jin, V.X.; et al. Spatiotemporal control of estrogen-responsive transcription in ERalpha-positive breast cancer cells. Oncogene 2016, 35, 2379–2389. [Google Scholar] [CrossRef] [Green Version]
- Crawford, N.T.; McIntyre, A.J.; McCormick, A.; D’Costa, Z.C.; Buckley, N.E.; Mullan, P.B. TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells. Oncogene 2019, 38, 5971–5986. [Google Scholar] [CrossRef] [Green Version]
- Kirschmann, D.A.; Seftor, E.A.; Nieva, D.R.; Mariano, E.A.; Hendrix, M.J. Differentially expressed genes associated with the metastatic phenotype in breast cancer. Breast Cancer Res. Treat. 1999, 55, 127–136. [Google Scholar] [CrossRef]
- Kirschmann, D.A.; Lininger, R.A.; Gardner, L.M.; Seftor, E.A.; Odero, V.A.; Ainsztein, A.M.; Earnshaw, W.C.; Wallrath, L.L.; Hendrix, M.J. Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. Cancer Res. 2000, 60, 3359–3363. [Google Scholar]
- Okamoto, K.; Tanaka, Y.; Ogasawara, S.; Obuse, C.; Nakayama, J.I.; Yano, H.; Tsuneoka, M. KDM2A-dependent reduction of rRNA transcription on glucose starvation requires HP1 in cells, including triple-negative breast cancer cells. Oncotarget 2019, 10, 4743–4760. [Google Scholar] [CrossRef] [Green Version]
- Maloney, A.; Clarke, P.A.; Naaby-Hansen, S.; Stein, R.; Koopman, J.O.; Akpan, A.; Yang, A.; Zvelebil, M.; Cramer, R.; Stimson, L.; et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2007, 67, 3239–3253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, W.; Wang, W.; Dong, H.; Li, Y.; Li, L.; Han, L.; Han, Z.; Wang, S.; Ma, D.; Wang, H. Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78. Oncol. Rep. 2014, 31, 2525–2534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pongas, G.; Kim, M.K.; Min, D.J.; House, C.D.; Jordan, E.; Caplen, N.; Chakka, S.; Ohiri, J.; Kruhlak, M.J.; Annunziata, C.M. BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1). Oncotarget 2017, 8, 51402–51415. [Google Scholar] [CrossRef] [PubMed]
- Huang, R.; Langdon, S.P.; Tse, M.; Mullen, P.; Um, I.H.; Faratian, D.; Harrison, D.J. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer. Oncotarget 2016, 7, 4695–4711. [Google Scholar] [CrossRef] [Green Version]
- Yi, S.A.; Lee, D.H.; Kim, G.W.; Ryu, H.W.; Park, J.W.; Lee, J.; Han, J.; Park, J.H.; Oh, H.; Lee, J.; et al. HPV-mediated nuclear export of HP1gamma drives cervical tumorigenesis by downregulation of p53. Cell Death Differ. 2020, 27, 2537–2551. [Google Scholar] [CrossRef] [Green Version]
- Yang, Y.; Liu, R.; Qiu, R.; Zheng, Y.; Huang, W.; Hu, H.; Ji, Q.; He, H.; Shang, Y.; Gong, Y.; et al. CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylation-based epigenetic silencing. Oncogene 2015, 34, 104–118. [Google Scholar] [CrossRef]
- Coussens, L.M.; Werb, Z. Matrix metalloproteinases and the development of cancer. Chem. Biol. 1996, 3, 895–904. [Google Scholar] [CrossRef] [Green Version]
- Eguchi, T.; Calderwood, S.K.; Takigawa, M.; Kubota, S.; Kozaki, K.I. Intracellular MMP3 Promotes HSP Gene Expression in Collaboration With Chromobox Proteins. J. Cell. Biochem. 2017, 118, 43–51. [Google Scholar] [CrossRef] [Green Version]
- Jiang, W.Q.; Nguyen, A.; Cao, Y.; Chang, A.C.; Reddel, R.R. HP1-mediated formation of alternative lengthening of telomeres-associated PML bodies requires HIRA but not ASF1a. PLoS ONE 2011, 6, e17036. [Google Scholar] [CrossRef] [Green Version]
- Li, Q.; Pan, Y.; Cao, Z.; Zhao, S. Comprehensive Analysis of Prognostic Value and Immune Infiltration of Chromobox Family Members in Colorectal Cancer. Front. Oncol. 2020, 10, 582667. [Google Scholar] [CrossRef]
- Liu, M.; Huang, F.; Zhang, D.; Ju, J.; Wu, X.B.; Wang, Y.; Wang, Y.; Wu, Y.; Nie, M.; Li, Z.; et al. Heterochromatin protein HP1gamma promotes colorectal cancer progression and is regulated by miR-30a. Cancer Res. 2015, 75, 4593–4604. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cheng, Y.; Geng, H.; Cheng, S.H.; Liang, P.; Bai, Y.; Li, J.; Srivastava, G.; Ng, M.H.; Fukagawa, T.; Wu, X.; et al. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res. 2010, 70, 6516–6526. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yi, S.A.; Ryu, H.W.; Lee, D.H.; Han, J.W.; Kwon, S.H. HP1beta suppresses metastasis of human cancer cells by decreasing the expression and activation of MMP2. Int. J. Oncol. 2014, 45, 2541–2548. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruginis, T.; Taglia, L.; Matusiak, D.; Lee, B.S.; Benya, R.V. Consequence of gastrin-releasing peptide receptor activation in a human colon cancer cell line: A proteomic approach. J. Proteome Res. 2006, 5, 1460–1468. [Google Scholar] [CrossRef]
- Tell, R.; Rivera, C.A.; Eskra, J.; Taglia, L.N.; Blunier, A.; Wang, Q.T.; Benya, R.V. Gastrin-releasing peptide signaling alters colon cancer invasiveness via heterochromatin protein 1Hsbeta. Am. J. Pathol. 2011, 178, 672–678. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bartova, E.; Pachernik, J.; Harnicarova, A.; Kovarik, A.; Kovarikova, M.; Hofmanova, J.; Skalnikova, M.; Kozubek, M.; Kozubek, S. Nuclear levels and patterns of histone H3 modification and HP1 proteins after inhibition of histone deacetylases. J. Cell Sci. 2005, 118, 5035–5046. [Google Scholar] [CrossRef] [Green Version]
- Gonzalez-Barrios, R.; Soto-Reyes, E.; Quiroz-Baez, R.; Fabian-Morales, E.; Diaz-Chavez, J.; Del Castillo, V.; Mendoza, J.; Lopez-Saavedra, A.; Castro, C.; Herrera, L.A. Differential distribution of HP1 proteins after trichostatin a treatment influences chromosomal stability in HCT116 and WI-38 cells. Cell Div. 2014, 9, 6. [Google Scholar] [CrossRef] [Green Version]
- Yu, Y.H.; Chiou, G.Y.; Huang, P.I.; Lo, W.L.; Wang, C.Y.; Lu, K.H.; Yu, C.C.; Alterovitz, G.; Huang, W.C.; Lo, J.F.; et al. Network biology of tumor stem-like cells identified a regulatory role of CBX5 in lung cancer. Sci. Rep. 2012, 2, 584. [Google Scholar] [CrossRef] [Green Version]
- Coleman, D.J.; Gao, L.; King, C.J.; Schwartzman, J.; Urrutia, J.; Sehrawat, A.; Tayou, J.; Balter, A.; Burchard, J.; Chiotti, K.E.; et al. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. Oncogene 2019, 38, 5658–5669. [Google Scholar] [CrossRef]
- Chen, S.; Wang, C.; Sun, L.; Wang, D.L.; Chen, L.; Huang, Z.; Yang, Q.; Gao, J.; Yang, X.B.; Chang, J.F.; et al. RAD6 promotes homologous recombination repair by activating the autophagy-mediated degradation of heterochromatin protein HP1. Mol. Cell. Biol. 2015, 35, 406–416. [Google Scholar] [CrossRef] [Green Version]
- Eriksson, M.; Haag, P.; Brzozowska, B.; Lipka, M.; Lisowska, H.; Lewensohn, R.; Wojcik, A.; Viktorsson, K.; Lundholm, L. Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment. Int. J. Radiat. Oncol. Biol. Phys. 2018, 100, 174–187. [Google Scholar] [CrossRef] [PubMed]
- Dutta, P.; Zhang, L.; Zhang, H.; Peng, Q.; Montgrain, P.R.; Wang, Y.; Song, Y.; Li, J.; Li, W.X. Unphosphorylated STAT3 in heterochromatin formation and tumor suppression in lung cancer. BMC Cancer 2020, 20, 145. [Google Scholar] [CrossRef] [PubMed]
- Xie, X.; Ning, Y.; Long, J.; Wang, H.; Chen, X. Diverse CBX family members as potential prognostic biomarkers in non-small-cell lung cancer. FEBS Open Bio. 2020, 10, 2206–2215. [Google Scholar] [CrossRef] [PubMed]
- Alam, H.; Li, N.; Dhar, S.S.; Wu, S.J.; Lv, J.; Chen, K.; Flores, E.R.; Baseler, L.; Lee, M.G. HP1gamma Promotes Lung Adenocarcinoma by Downregulating the Transcription-Repressive Regulators NCOR2 and ZBTB7A. Cancer Res. 2018, 78, 3834–3848. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, S.C.; Lai, Y.C.; Chen, Y.C.; Wang, N.K.; Wang, W.S.; Lai, J.I. CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer. Asia-Pac. J. Clin. Oncol. 2018, 14, e283–e288. [Google Scholar] [CrossRef]
- Zhong, X.; Kan, A.; Zhang, W.; Zhou, J.; Zhang, H.; Chen, J.; Tang, S. CBX3/HP1gamma promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma. Aging 2019, 11, 5483–5497. [Google Scholar] [CrossRef]
- Yang, Y.F.; Pan, Y.H.; Tian, Q.H.; Wu, D.C.; Su, S.G. CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma. Transl. Oncol. 2018, 11, 1110–1118. [Google Scholar] [CrossRef]
- Zheng, Q.; Xu, J.; Lin, Z.; Lu, Y.; Xin, X.; Li, X.; Yang, Y.; Meng, Q.; Wang, C.; Xiong, W.; et al. Inflammatory factor receptor Toll-like receptor 4 controls telomeres through heterochromatin protein 1 isoforms in liver cancer stem cell. J. Cell. Mol. Med. 2018, 22, 3246–3258. [Google Scholar] [CrossRef]
- Wu, M.; An, J.; Zheng, Q.; Xin, X.; Lin, Z.; Li, X.; Li, H.; Lu, D. Double mutant P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDR. Oncotarget 2016, 7, 66525–66539. [Google Scholar] [CrossRef]
- Chen, L.Y.; Cheng, C.S.; Qu, C.; Wang, P.; Chen, H.; Meng, Z.Q.; Chen, Z. Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression. Int. J. Mol. Sci. 2018, 19, 1768. [Google Scholar] [CrossRef] [Green Version]
- Baumgart, S.; Glesel, E.; Singh, G.; Chen, N.M.; Reutlinger, K.; Zhang, J.; Billadeau, D.D.; Fernandez-Zapico, M.E.; Gress, T.M.; Singh, S.K.; et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology 2012, 142, 388–398.E7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, L.Y.; Cheng, C.S.; Qu, C.; Wang, P.; Chen, H.; Meng, Z.Q.; Chen, Z. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Biochem. Biophys. Res. Commun. 2018, 500, 691–697. [Google Scholar] [CrossRef] [PubMed]
- Lomberk, G.; Mathison, A.J.; Grzenda, A.; Seo, S.; DeMars, C.J.; Rizvi, S.; Bonilla-Velez, J.; Calvo, E.; Fernandez-Zapico, M.E.; Iovanna, J.; et al. Sequence-specific recruitment of heterochromatin protein 1 via interaction with Kruppel-like factor 11, a human transcription factor involved in tumor suppression and metabolic diseases. J. Biol. Chem. 2012, 287, 13026–13039. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jenster, G. The role of the androgen receptor in the development and progression of prostate cancer. Semin. Oncol. 1999, 26, 407–421. [Google Scholar] [PubMed]
- Heinlein, C.A.; Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 2004, 25, 276–308. [Google Scholar] [CrossRef] [Green Version]
- Shiota, M.; Song, Y.; Yokomizo, A.; Tada, Y.; Kuroiwa, K.; Eto, M.; Oda, Y.; Inokuchi, J.; Uchiumi, T.; Fujimoto, N.; et al. Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth. Endocr. Relat. Cancer 2010, 17, 455–467. [Google Scholar] [CrossRef] [Green Version]
- Itsumi, M.; Shiota, M.; Yokomizo, A.; Kashiwagi, E.; Takeuchi, A.; Tatsugami, K.; Inokuchi, J.; Song, Y.; Uchiumi, T.; Naito, S. Human heterochromatin protein 1 isoforms regulate androgen receptor signaling in prostate cancer. J. Mol. Endocrinol. 2013, 50, 401–409. [Google Scholar] [CrossRef] [Green Version]
- Slezak, J.; Truong, M.; Huang, W.; Jarrard, D. HP1gamma expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy. BMC Cancer 2013, 13, 148. [Google Scholar] [CrossRef] [Green Version]
- Chang, C.; Liu, J.; He, W.; Qu, M.; Huang, X.; Deng, Y.; Shen, L.; Zhao, X.; Guo, H.; Jiang, J.; et al. A regulatory circuit HP1gamma/miR-451a/c-Myc promotes prostate cancer progression. Oncogene 2018, 37, 415–426. [Google Scholar] [CrossRef]
- Ma, C.; Nie, X.G.; Wang, Y.L.; Liu, X.H.; Liang, X.; Zhou, Q.L.; Wu, D.P. CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma. Mol. Med. Rep. 2019, 19, 4205–4212. [Google Scholar] [CrossRef] [Green Version]
- Kalousi, A.; Hoffbeck, A.S.; Selemenakis, P.N.; Pinder, J.; Savage, K.I.; Khanna, K.K.; Brino, L.; Dellaire, G.; Gorgoulis, V.G.; Soutoglou, E. The nuclear oncogene SET controls DNA repair by KAP1 and HP1 retention to chromatin. Cell Rep. 2015, 11, 149–163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Munro, S.; Khaire, N.; Inche, A.; Carr, S.; La Thangue, N.B. Lysine methylation regulates the pRb tumour suppressor protein. Oncogene 2010, 29, 2357–2367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saini, V.; Hose, C.D.; Monks, A.; Nagashima, K.; Han, B.; Newton, D.L.; Millione, A.; Shah, J.; Hollingshead, M.G.; Hite, K.M.; et al. Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS ONE 2012, 7, e41401. [Google Scholar] [CrossRef]
- Zhao, S.P.; Wang, F.; Yang, M.; Wang, X.Y.; Jin, C.L.; Ji, Q.K.; Li, S.; Zhao, X.L. CBX3 promotes glioma U87 cell proliferation and predicts an unfavorable prognosis. J. Neurooncol. 2019, 145, 35–48. [Google Scholar] [CrossRef] [PubMed]
- Lukasova, E.; Koristek, Z.; Falk, M.; Kozubek, S.; Grigoryev, S.; Kozubek, M.; Ondrej, V.; Kroupova, I. Methylation of histones in myeloid leukemias as a potential marker of granulocyte abnormalities. J. Leukoc. Biol. 2005, 77, 100–111. [Google Scholar] [CrossRef] [PubMed]
- Popova, E.Y.; Claxton, D.F.; Lukasova, E.; Bird, P.I.; Grigoryev, S.A. Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood. Exp. Hematol. 2006, 34, 453–462. [Google Scholar] [CrossRef] [PubMed]
- Imanishi, S.; Umezu, T.; Kobayashi, C.; Ohta, T.; Ohyashiki, K.; Ohyashiki, J.H. Chromatin Regulation by HP1gamma Contributes to Survival of 5-Azacytidine-Resistant Cells. Front. Pharmacol. 2018, 9, 1166. [Google Scholar] [CrossRef]
- Lin, K.; Zhu, J.; Hu, C.; Bu, F.; Luo, C.; Zhu, X.; Zhu, Z. Comprehensive analysis of the prognosis for chromobox family in gastric cancer. J. Gastrointest. Oncol. 2020, 11, 932–951. [Google Scholar] [CrossRef]
- Lin, H.; Lian, J.; Xia, L.; Guan, G.; You, J. CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses. Cancer Manag. Res. 2020, 12, 10113–10125. [Google Scholar] [CrossRef]
- Nishimura, K.; Hirokawa, Y.S.; Mizutani, H.; Shiraishi, T. Reduced heterochromatin protein 1-beta (HP1beta) expression is correlated with increased invasive activity in human melanoma cells. Anticancer Res. 2006, 26, 4349–4356. [Google Scholar]
- Tretiakova, M.S.; Bond, S.D.; Wheeler, D.; Contreras, A.; Kocherginsky, M.; Kroll, T.G.; Hale, T.K. Heterochromatin protein 1 expression is reduced in human thyroid malignancy. Lab. Investig. 2014, 94, 788–795. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, R.; Adams, P.D. Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle 2007, 6, 784–789. [Google Scholar] [CrossRef] [PubMed]
- Cheng, Y.; He, C.; Wang, M.; Ma, X.; Mo, F.; Yang, S.; Han, J.; Wei, X. Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct. Target. Ther. 2019, 4, 62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cruz, A.L.S.; Barreto, E.A.; Fazolini, N.P.B.; Viola, J.P.B.; Bozza, P.T. Lipid droplets: Platforms with multiple functions in cancer hallmarks. Cell Death Dis. 2020, 11, 105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Cancer Type | HP1 Subtype | Altered Expression in Cancer | Role in Cancer |
---|---|---|---|
Breast cancer | HP1α | Increased | Promotes tumorigenesis |
Decreased | Suppresses metastasis | ||
HP1β | Increased | Promotes tumorigenesis | |
HP1γ | - | Controversial | |
Ovarian cancer | HP1α | - | - |
HP1β | - | - | |
HP1γ | - | - | |
Cervical cancer | HP1α | - | - |
HP1β | - | - | |
HP1γ | Increased | Promotes tumorigenesis | |
Colorectal cancer | HP1α | Increased | Promotes tumorigenesis |
HP1β | Increased | Promotes tumorigenesis | |
Decreased | Suppresses metastasis | ||
HP1γ | Increased | Promotes tumorigenesis | |
Lung cancer | HP1α | Increased | Promotes tumorigenesis |
HP1β | Increased | Promotes tumorigenesis | |
HP1γ | Increased | Promotes tumorigenesis | |
Liver cancer | HP1α | - | - |
HP1β | Increased | Promotes tumorigenesis | |
HP1γ | Increased | Promotes tumorigenesis | |
Pancreatic cancer | HP1α | - | - |
HP1β | - | - | |
HP1γ | Increased | Promotes tumorigenesis | |
Prostate cancer | HP1α | - | - |
HP1β | Increased | Promotes tumorigenesis | |
HP1γ | Increased | Promotes tumorigenesis | |
Osteosarcoma | HP1α | - | - |
HP1β | - | - | |
HP1γ | Increased | Promotes tumorigenesis | |
Glioma | HP1α | - | - |
HP1β | - | - | |
HP1γ | Increased | Promotes tumorigenesis | |
Leukemia | HP1α | Increased | Promotes tumorigenesis |
HP1β | Increased | Promotes tumorigenesis | |
HP1γ | Increased | Promotes tumorigenesis | |
Gastric cancer | HP1α | - | - |
HP1β | - | - | |
HP1γ | Increased | Promotes tumorigenesis | |
Multiple myeloid | HP1α | - | - |
HP1β | - | - | |
HP1γ | - | - | |
Melanoma | HP1α | - | - |
HP1β | Decreased | Suppresses metastasis | |
HP1γ | - | - | |
Thyroid cancer | HP1α | - | - |
HP1β | Decreased | Promotes tumorigenesis/Suppresses metastasis | |
HP1γ | Decreased | Promotes tumorigenesis/Suppresses metastasis |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jeon, Y.H.; Kim, G.W.; Kim, S.Y.; Yi, S.A.; Yoo, J.; Kim, J.Y.; Lee, S.W.; Kwon, S.H. Heterochromatin Protein 1: A Multiplayer in Cancer Progression. Cancers 2022, 14, 763. https://doi.org/10.3390/cancers14030763
Jeon YH, Kim GW, Kim SY, Yi SA, Yoo J, Kim JY, Lee SW, Kwon SH. Heterochromatin Protein 1: A Multiplayer in Cancer Progression. Cancers. 2022; 14(3):763. https://doi.org/10.3390/cancers14030763
Chicago/Turabian StyleJeon, Yu Hyun, Go Woon Kim, So Yeon Kim, Sang Ah Yi, Jung Yoo, Ji Yoon Kim, Sang Wu Lee, and So Hee Kwon. 2022. "Heterochromatin Protein 1: A Multiplayer in Cancer Progression" Cancers 14, no. 3: 763. https://doi.org/10.3390/cancers14030763